Biomarkers in early drug development
The EMA glossary defines a biological marker, or biomarker, as ‘an objective and quantifiable measure of a physiological process, pathological process or response to a treatment (excluding measurements of how…
Evaluation of drug safety does not start at candidate nomination: Create value by de-risking early
Drug development is a daunting and difficult task where all the puzzle pieces need to click to result in an efficacious and safe treatment for patients. It is a…
Unleashing the Power of Drug Repurposing
Drug repurposing, also called drug repositioning, reprofiling or retasking, is the process of identifying a new use for an existing medicine/active substance outside the scope of the original indication(s). It…
Inez de Greef elected to the NAE
Inez de Greef elected as fellow of the Netherlands Academy of Engineering We are thrilled to announce that Inez de Greef, CEO of Treeway and co-founder and Managing Partner of…
Knowledge for Growth 2023
Knowledge for Growth, Europe’s leading conference in the field of life sciences, is set to take place in Antwerp, Belgium on June 1, 2023. This exceptional event will bring together…
Ronald van der Geest shares his experience as a speaker
Fast-track drug development: taking the highway or the roundabout? In a race against time, costs and competitors, the pharmaceutical industry finds itself at a crossroads. As the world demands faster…
CR2O and 3D-PharmXchange are celebrating and securing the successful ongoing collaboration
A successful drug development strategy is a well-designed and dynamic process. Making sure regulatory requirements are embedded from the start, is key. From pre-clinical all the way to registration, a…
2023 Conferences & Events
3D-PharmXchange will be attending, exhibiting and/or presenting at the following conferences and events in 2023: Click on the event name for more information. Event Date(s) Location Exhibitor/Attendee World ADC March…
Cell Therapy: Towards a First-in-Human Trial
The proof-of-concept studies have shown promising results and bring a therapy a step closer to the clinic. But what is needed before this therapy can show its efficacy in a…
Leadership At Treeway
In 2013, Inez de Greef – van der Sandt was appointed as CEO for our client Treeway, a biotechnology company with a mission to develop therapies to cure ALS. Treeway…